The global CGM market has surpassed $10 billion in annual revenues and is dominated by just a few players who collectively control nearly the entire market. For companies competing in or entering this space, tracking the moves of these leaders is critical to staying ahead.
This sample report provides an overview of Medtronic’s recent activities in continuous glucose monitoring (CGM), highlighting how one of the industry’s pioneers is adapting to a rapidly evolving competitive landscape.
Inside the Sample
This Medtronic-focused analysis highlights:
- Product Launches & Innovations: An overview of Medtronic’s latest CGM and insulin delivery systems, including sensor upgrades, new designs, and integrated innovative therapy solutions.
- Strategic Moves: Key partnerships, acquisitions, and attempted deals that reveal Medtronic’s motivations.
- Intellectual Property & Research: Insights into Medtronic’s patent activity, R&D priorities, and published real-world evidence that support adoption.
- Market Context: An overview of how Medtronic stacks up against leading competitors like Abbott and Dexcom in global market share.
Medtronic is among the top 3 providers for continuous glucose monitoring. Understanding its R&D priorities, partnerships, and market plays is crucial for anyone assessing the future of glucose monitoring.
👉 Download this free sample on Medtronic:
About the Paid Competitive Analysis Report
This sample is part of GreyB’s Paid Competitive Intelligence Report on the Global CGM Market. The full report covers all leading players, Dexcom, Abbott, Medtronic, Senseonics, and others, providing:
- Competitive benchmarking
- Patent landscapes
- M&A and partnership tracking
- Strategic outlook for 2026 and beyond
👉 Request this paid report here.